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Abstract
Perivascular adipose tissue (PVAT) has emerged in the past decades as an integral part of the vasculature (tunica adiposa), con-
tributing by the release of adipokines, to important physiological process such as vascular tone regulation. The metabolic syn-
drome is associated with an increase deposition of PVAT and the development of atherosclerosis. Whereas healthy PVAT protect 
the vasculature from inflammation, lipid accumulation and hypothermia, the dysfunctional PVAT observed in the metabolic 
syndrome favour many features of atherosclerosis such as endothelial dysfunction, vascular smooth muscle proliferation and 
inflammation. The down- and up-regulation of adiponectin, leptin and nerve growth factor, respectively in the dysfunctional 
PVAT perfectly illustrates this change. Phenotypically, healthy PVAT resembles the thermogenic brown and beige adipocytes, 
however, recent data suggest a loss of PVAT thermogenic phenotype during the metabolic syndrome in a process called “PVAT 
whitening”. This review will provide a current perspective on the factors susceptible to influence PVAT epigenetics and the con-
sequences of PVAT dysfunction on cardiometabolic diseases.  
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Prologue
In our post-industrial society, the combination of the abundance 
of processed food, sedentary life style, stress, and exposure to 
endocrine disruptor favours the explosion of obesity. According 
to the World Health Organization (WHO) obesity has doubled 
since 1980, and by 2030 some studies suggest that almost half 
(42%) of adult in the United States could be affected (Finkelstein 
et al. 2012). During the same period the burden of cardiometa-
bolic diseases (CMD) has also grown making them for the first 
time in human history the leading cause of premature mortal-
ity ahead of infectious diseases (WHO report 2008). About 260 
years ago the Italian physician Morgagni described the associa-
tion between hyperuricemia, visceral obesity, hypertension, ob-
structive sleep apnoea and atherosclerosis (Crepaldi et al. 2006). 
It was not before 1998 that the term metabolic syndrome was 
defined by the WHO as a syndrome comprising type 2 diabetes 
or impaired glucose tolerance associated with at least two out of 
the four other factors, namely high blood pressure, high blood 
fat, obesity and microalbuminuria (Grundy et al. 2004, Crepaldi 
et al. 2006). Since then the scientific community has deployed 
constant effort to understand the interconnections between the 
different components of the metabolic syndrome leading to ath-
erosclerosis development.
Introduction
Adipose tissue is widely distributed throughout the human body 
and can be subdivided according to its anatomical location. 
Subcutaneous adipose tissue (SAT) and visceral adipose tissue 
(VAT) are the main pools of adipose tissue and account for 82-
97% and 10-15% of total body fat respectively (Gastaldelli et al. 
2010, Lee et al. 2013). However, small adipose tissue depots are 
also found in the bone marrow, skeletal muscles and mammary 
glands (Rosen et al. 2014). In the past decades perivascular adi-
pose tissue (PVAT) has emerged as an integral part (tunica adipo-
sa) of human arteries (Chaldakov et al. 2009, 2012, 2014; Ayala-
Lopez and Watts 2016) and veins of large, medium and small 
sizes with the notable exception of cerebral vessels (Houben et 
al. 2012, Szasz et al. 2013, Brown et al. 2014), and represent an 
average of 3% of total fat in human (Gastaldelli et al. 2010; Lee 
et al. 2013). In the small vessels of some organs, however, PVAT 
may be constituted by the adipose depots embedding this organ 
as it is the case for the pericoronary/epicardial PVAT (Britton 
et al. 2011). It is now accepted that PVAT is not only a connec-
tive tissue, providing the vessel with mechanical protection, but 
also a regulator of vascular functions through the secretion of 
many adipokines with vasoactive, pro- and anti-inflammatory, 
and neuro-metabotrophic properties (Chaldakov et al. 2014; 
Kostopoulos et al. 2014; Iacobellis 2016). Although adipocytes 
are the main component of PVAT it also consists of nerves and 
resident immune cells (e.g. macrophages, mast cells) whose in-
teractions ensure vascular homeostasis (Chaldakov et al. 2014, 
Ayala-Lopez and Watts 2016). Whereas SAT and VAT are the 
main contributors to the systemic adipokines level, the proxim-
ity of PVAT with the vasa vasorum may allow PVAT-derived 
adipokines to reach the inner vascular cells (i.e. vascular smooth 
muscle and endothelial cells) at high concentration and there-
by strongly impact vascular function. Thus, it has been shown 
that PVAT exert anticontractile functions through the release of 
adipose derived relaxing factors (ADRF) such as adiponectin, 
hydrogen sulphide (H2S), NO and prostacyclin (Wojcicka et al. 
2011, Nava et al. 2016). On the other hand, PVAT can mediate 
nerve dependant vasoconstriction by releasing adipose derived 
constricting factors (ADCF) such as superoxide anion, angio-
tensin II and endothelin-1 (Gao et al. 2007). 
Obesity is associated with an increase in PVAT deposition, 
which is strongly related to atherosclerotic plaque development 
(Mahabadi et al. 2010, Maurovich-Horvat et al. 2011). Moreover, 
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in a swine model of obesity the increases in PVAT deposition 
negatively correlate with coronary vasodilatation (Owen et al. 
2013). Accumulating data suggest also a phenotypic switch of 
PVAT during metabolic syndrome development which can 
be summarized under the term “PVAT dysfunction”. The dys-
functional PVAT is characterized by a loss of its anticontractile 
property, and an increase in the release of proinflammatory and 
proangiogenic adipokines (Chang et al. 2013; Kostopoulos et al. 
2014). These adipokines, by promoting endothelial dysfunction, 
macrophage chemotaxis, together with the proliferation of vas-
cular SMC and fibroblasts, contribute to the vascular remodel-
ling and the progression of atherosclerotic plaque. On the other 
hand, when compared to other fat depots such as SAT and VAT, 
mouse PVAT was found to be resistant to a high fat diet (HFD) 
induced inflammation (Fitzgibbons et al. 2011). The protective 
role of PVAT could be linked to its thermogenic potential that 
regulates intravascular temperature, increases plasma triglycer-
ide clearance and confer resistance to inflammation. Therefore, 
it is important to identify the molecular (i.e. Mediators, signal-
ling pathway, epigenetic factor) determinants of PVAT pheno-
type in health and disease. Several studies suggest that in utero 
and long term exposure to the metabolic syndrome could lead to 
a loss of PVAT thermogenic ability by modifying its epigenetic 
memory. In the past decades epigenetics has emerged as a new 
level of gene regulation involving modification of DNA acces-
sibility by post-translational modification of histones (e.g. phos-
phorylation, acetylation, and methylation) and DNA methyla-
tion. Recent studies in humans (Mamun et al. 2009, Oken 2009, 
Fraser et al. 2010) and rodents (Samuelsson et al. 2008, Shankar 
et al. 2008) models have shown the links between maternal obe-
sity or weight gain during pregnancy and metabolic disorders 
such as obesity, glucose intolerance and CMD in offspring. In 
this review, we are presenting the recent evidences of epigenetic 
regulation of adipocytes phenotype relevant to PVAT biology in 
health and disease.
PVAT phenotype in the spectrum of adipocytes 
phenotype
In addition to differences in location, there are also substantial 
functional differences between adipose tissue depots. Two main 
types of adipocytes are distinguished in human and mouse. 
Most adipocytes of SAT and VAT constitute the white adipose 
tissue (WAT). The white adipocytes constituting WAT are char-
acterized by a unilocular large lipid droplets, small peripheral 
nucleus, few mitochondria’s and are mainly responsible for ener-
gy storage in the form of lipids (Rosen et al. 2014). On the other 
hand thermogenic or brown adipose tissue (BAT) in humans is 
found in cervical, supraclavicular, paravertebral, mediastinal, 
and peri-renal regions (Sacks et al. 2013). The brown adipocytes 
constituting BAT are smaller, present multilocular lipid droplets, 
centralized nucleus, and higher numbers of mitochondria. The 
main physiological function of brown adipocyte is to maintain 
body temperature and avoid hypothermia. The thermogenic ca-
pacity of brown adipocytes relies on the expression of the un-
coupling protein-1 (UCP-1) within the mitochondria (Rosen 
et al. 2014). This protein by catalysing a proton leak across the 
inner mitochondrial membrane disconnect fatty acid oxidation 
from ATP production, thus producing heat (Rosen et al. 2014). 
Recently a third category of adipocyte called beige or brite (for 
brown in white adipocytes) has been characterized (Chechi et 
al. 2013). These cells are mainly induced in SAT by stimuli such 
as cold exposure and β-adrenergic stimulation. Similar to brown 
adipocytes, beige adipocytes express high levels of UCP-1 whose 
expression is required for their thermogenic function (Lee et al. 
2013). In human most studies on PVAT has been made on the 
pericoronary/epicardial and periaortic adipose tissue and con-
clude that human PVAT phenotype resembles beige/brown adi-
pocytes and is characterized by a small size, multilocular lipid 
droplets, abundant mitochondria, as well as high expression of 
UCP-1 (Sacks et al. 2013, Brown et al. 2014). In agreement with 
the findings in human, studies in mice showed that aortic PVAT 
present a large similarity to BAT and is also resistant to diet-in-
duced inflammation (Fitzgibbons et al. 2011). Brown adipocytes 
in rodents has been shown to improve several characteristics of 
the metabolic syndrome, such as hyperglycaemia, insulin resist-
ance and the excess of free fatty acid characterizing dyslipidae-
mia (Bartelt et al. 2011, Shimizu et al. 2015, Villarroya 2016). In 
accordance with a similar protective effect of PVAT, Chang et 
al showed that PVAT free mice had impaired ability to regulate 
triglyceride levels and intravascular temperature (Chang et al. 
2012). In conclusion the thermogenic potential of most PVAT 
depots (with the exception of mesenteric PVAT) is associated 
with vasculoprotective functions. Therefore, it is crucial to un-
derstand the mechanisms regulating PVAT thermogenic pheno-
type, and PVAT dysfunction in order to prevent, and manage the 
vascular diseases associated with the metabolic syndrome.
Role of epigenetics in adipocytes differentiation and 
PVAT phenotypic diversity
From a developmental perspective, brown and white adipocytes 
arise from two different precursors (Fig. 1A). Whereas brown 
adipocytes derived from a Pax7+/Myf5+ stem cells involved in 
skeletal muscle development, white and beige adipocytes are 
derived from a common PAX7-/Myf5-/PDGFR-α+ precur-
sor (Brown et al. 2014). In a very interesting article Chang et 
al demonstrated that specific deletion of PPARγ in SM22α ex-
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pressing cells (i.e. Vascular smooth muscle cells) impairs aortic 
and mesenteric PVAT development without any effect on BAT 
and WAT development (Chang et al. 2012). This strongly sug-
gests that mouse PVAT derived from a precursor of the vas-
cular smooth muscle cell lineage. Consequently, compared to 
others fat depots such as SAT, PVAT present a reduced adipo-
genic potential and a heightened pro-inflammatory phenotype 
(Chatterjee et al. 2009, Gil-Ortega et al. 2015). Despite these 
differences in origin, both brown and beige adipocytes express 
the transcription factor PRDM16 which play a critical role in 
the thermogenic differentiation of adipocytes. Interestingly, it 
has been shown that PRDM16 promotes the thermogenic differ-
entiation of adipocytes through its association with the euchro-
matic histone-lysine N-methyltransferase 1 (EHMT1). Through 
this interaction PRDM16 repress the genetic program leading 
to skeletal muscle differentiation (Ohno et al. 2013). Similar 
to PVAT development, it has been shown recently that a sub-
set of beige adipocytes induced by cold, is derived from a vas-
cular smooth muscle cell (SMC) precursor expressing myosin 
heavy chain 11 (Myh11+) (Long et al. 2014, Berry et al. 2016). 
Interestingly the expression of PRDM16 in vascular smooth 
muscle cells is able to turn them into beige adipocytes (Long et 
al. 2014). This suggests that PRDM16 through interactions with 
EHMT1 or another epigenetic regulator could repress vascular 
smooth muscle cell differentiation in the SM22α+ precursor and 
promote PVAT differentiation. This hypothesis is also supported 
by the fact that human epicardial adipose tissue (peri-coronary 
adipose tissue) display great similarities with beige adipocytes 
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Figure 1. A. Representation of adipocytes foetal programming induced by in utero exposure to a high fat diet (HFD). Epigenetics 
plays an important role in the development of most tissues including adipose tissue and allow the generation of brown (BAT), 
brown in white (BRITE), white (WAT) and perivascular (PVAT) adipose tissue depots from mesenchymal/mesodermal stem cells 
(Siersbaek et al. 2012). In utero exposure to a HFD, by generating inflammation and the loss of metabolic homeostasis induces 
a reduction of thermogenic adipocytes while inducing WAT hypertrophy and PVAT “whitening”. Whether this alteration also 
affects the generation of the intermediate progenitors remains unknown. Adapted from (Brown et al. 2014). B. Hypothetical 
model of adipose tissue phenotype diversity based on location. According to the results of Satoor et al. (2011) adipose tissues 
location define their exposure to local parameters such as glucose concentration ([glucose]), leading to epigenetic regulation 
of their phenotype. Beyond [glucose] other mediators derived from nearby resident cells, such as, cytokines, growth factors 
may also regulate adipocytes phenotype through epigenetic regulation resulting in specific phenotypes and functions. * Not 
applicable to mesenteric PVAT.
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(Sacks et al. 2013). Despite a common developmental path 
PVAT phenotype varies according to location in human and 
mouse. Thus, in mice the phenotype of PVAT in the thoracic 
aorta resembles BAT, whereas mesenteric PVAT resembles WAT. 
Finally, aortic and renal adipocytes resembles beige adipocytes 
(Brown et al. 2014). These observations support a high plasticity 
of PVAT adipocytes and the critical role of environmental and 
cellular interactions in adipocytes phenotype. In a remarkable 
work, Satoor et al showed that transfer of VAT in the subcuta-
neous space was able to modify the phenotype of the engrafted 
VAT by modifying its epigenetic memory (Satoor et al. 2011). 
Indeed, they showed that the high glucose concentration in the 
mesenteric circulation was able to epigenetically repress VAT 
expression of adipokines (i.e. adiponectin, leptin, resistin and 
visfatin) by recruiting the histone demethylase LSD1 and KMT1 
(Satoor et al. 2011). This could explain the fact that mesenteric 
PVAT unlike others present a phenotype of white adipocytes. 
Interestingly, diabetes, which is characterized by hyperglycae-
mia is associated with PVAT inflammation that may result from 
a “PVAT whitening” (Lastra et al. 2015). Beyond glucose con-
centration other physiological parameters varying with location, 
such as temperature, exposure to myokines, inflammatory and 
neuromediators have been shown to influence the terminal dif-
ferentiation of adipocytes (Wang et al. 2016). This suggests that 
the phenotype of each fat depot results from the sensing and 
integration of many environmental factors and that, epigenetics 
may be a critical mechanism controlling adipose tissue diver-
sity and adaptation (Fig. 1B). By screening a collection of epi-
genetic compounds recently identified the histone demethylase 
LSD1/KDM1 as a key regulator of brown adipogenesis (Chen 
et al. 2016). Using RNA interference and knock-out mice, they 
further demonstrated that LSD1/KDM1 promotes brown adi-
pogenesis through Wnt pathway inhibition and stimulation of 
UCP-1 expression (Chen et al. 2016). In another study KDM1A 
has been shown to promote adipogenic differentiation and re-
press the expression of inflammatory mediators (i.e. IL-6) in the 
3T3-L1 pre-adipocyte cell line (Hanzu et al. 2013). Although the 
role of LSD1/KDM1 in PVAT has not been studied yet it is in-
teresting to notice that LSD1/KDM1 deficient mice (i.e. LSD1/
KDM1+/-) are more sensitive then there WT counterpart to salt 
induced hypertension due to alterations in NO-cGMP induced 
vascular relaxation (Pojoga et al. 2011). Whether this phenotype 
is due to a “PVAT whitening” remain to be demonstrated. This 
illustrates the potential role of epigenetic factors controlling the 
thermogenic adipocyte program in vascular biology. In a recent 
article Inagaki et al provided a complete review of the transcrip-
tional and epigenetic regulators controlling brown and beige 
adipocytes differentiation that could be used to further inves-
tigate the path of PVAT development and function (Inagaki et 
al. 2016).
In an effort to uncover the mechanisms behind adipocytes 
phenotypic diversity Gehrke et al (2003) studied the DNA 
methylation profile of different fat depots (i.e. abdominal and 
gluteal) in humans. They showed that DNA methylation profile 
of genes involved in fatty acid and triglyceride metabolism cor-
relates with their levels of expression in these depots resulting in 
differential fatty acid and triglycerides saturation. These results 
clearly demonstrate that epigenetic regulation is an important 
aspect of adipocytes functional diversity. But recent data’s also 
suggest a role for epigenetic regulation in dysfunctional adipo-
cytes. Indeed,  increases in the DNA methylation profile of genes 
relevant to adiposity in SAT of humans correlate with body mass 
index (BMI), android adipose mass, android:gynoid adipose ra-
tio and trunk:limb adipose ratio (Agha et al. 2015). Moreover, 
differential methylation of genes related to obesity has also been 
reported in the SAT of obese woman (Arner et al. 2015) and 
post-obese woman whose obesity is characterized by adipocytes 
hyperplasia (Dahlman et al. 2015). Thereby, epigenetic modifi-
cations such as histones and DNA methylation are not only in-
volved in adipocytes differentiation, but also in the maintenance 
of depots specific phenotype and the acquisition of a pathologic 
phenotype in patients with obesity. 
PVAT dysfunction caused by fetal programming
Further evidences of the epigenetic regulation of PVAT pheno-
type in health and disease has been brought by experimental 
models of foetal programming (Fig. 1A). In these models the 
foetus undergoing epigenetic regulation of its fat development is 
exposed to a pathologic maternal milieu induced by HFD (Laker 
2013). The interference of this pathological maternal milieu (i.e. 
hyperglycaemia, dyslipidaemia and inflammation) with the on-
going epigenetic regulation of adipogenesis results in obesity, 
glucose intolerance and CMD in the offspring that are transmit-
ted to the next generations (Laker 2013). Thus, Zaborska et al 
(2016) recently showed that the offspring of obese rats fed an 
HFD during pregnancy and lactation lost the anticontractile 
function of their PVAT despite being fed a normal diet for 12 or 
24 weeks after weaning. Furthermore this loss of anticontractile 
function resulted in hypertension at 24 weeks old of age. From a 
mechanistic perspective, the study showed that the loss of anti-
contractile effect of PVAT was due to the release of ADCF and 
a decrease in nitric oxide (NO) bioavailability (Zaborska et al. 
2016). This study suggests that in utero exposure to metabolic 
and adipokines imbalance, could imprint a pathological mem-
ory in adipocytes predisposing the offspring to hypertension. 
Beyond the loss of anti-contractile properties, in utero exposure 
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to a HFD has also been shown to favour atherosclerosis develop-
ment and a pro-inflammatory phenotype of PVAT especially by 
increasing the expression of the chemokines MCP-1 (Wakana 
et al. 2015). The contribution of PVAT dysfunction to athero-
sclerosis development has been further demonstrated by trans-
plantation experiments. Indeed transplantation of PVAT from 8 
weeks old mice exposed in utero to a HFD was associated with a 
twofold increased in atherosclerotic plaque development in the 
nearby artery when compared to transplantation of PVAT from 
mice exposed in utero to a normal diet (Wakana et al. 2015).  A 
recent report also showed that coronary atherosclerosis induced 
by a HFD is accompanied by a transition of the epicardial fat phe-
notype from brown to white (Wang et al. 2015). This transition 
was characterized by a decrease in the number of mitochondria 
as well as in the expression of UCP-1 and PPARγ (Wang et al. 
2015). Consistently it has been shown that the offspring of mice 
fed a HFD during lactation present a reduction in BAT depots 
and a reduced thermogenic capacity of their adipocytes (Liang 
et al. 2016). One of the major regulator of PPARγ function and 
UCP-1 expression during the development of thermogenic 
adipocytes is the peroxisome proliferator-activated receptor γ 
coactivator-1α (Pgc-1α). Interestingly a HFD has been shown to 
repress PGC-1α expression in skeletal muscle through methyla-
tion of its promoter (Laker et al. 2014). Thus the epigenetic re-
pression of PGC-1α in PVAT could explain the impaired UCP-1 
and PPARγ expression observed in epicardial fat of rats exposed 
to a HFD. UCP-1 expression in adipocytes has been shown to be 
regulated through both DNA methylation and histones modifi-
cation in response to cold exposure (Shore et al. 2010). The det-
rimental effect of a possible “PVAT whitening” on atherosclero-
sis development is provided by transplant experiments showing 
that VAT transplant is more proatherogenic than SAT which in-
clude numbers of thermogenic (i.e. beige adipocytes) adipocytes 
(Ohman et al. 2011). It is therefore important to find new targets 
allowing the maintenance of PVAT thermogenic phenotype and 
the prevention of its “whitening”.
Effect of exercise training on PVAT function and 
adipocytes thermogenic program
Whereas in utero exposure to a HFD is associated with PVAT 
“whitening” in offspring, studies on the effect of exercise train-
ing suggest a possible “re-browning” of PVAT. Indeed, in a rat 
model of metabolic syndrome (i.e. obese Zucker rats) associated 
with PVAT dysfunction (i.e. loss of anti-contractile function, de-
creased UCP-1 expression, increased inflammatory mediator ex-
pression) exercise training have been shown to improve UCP-1 
expression and to inhibit the release of IL-6 and TNFα by PVAT 
(DeVallance et al. 2016). Recent reports showed that exercise 
training was able to improve the dysfunction of adipocytes in-
duced by a HFD in rats through induction of beige adipocytes in 
their WAT. The authors observed an exercise dependant increase 
in fibronectin type III domain-containing protein 5 (FNDC5) 
the precursor of the myokine irisin (Rocha-Rodrigues et al. 
2016, Rocha-Rodrigues et al. 2016; for exercise-adiponectin link 
see Öztürk et al in this volume of Adipobiology). Previously irisin 
has been reported to induce white fat browning through stimu-
lation of UCP-1 expression (Bostrom et al. 2012). Interestingly 
a recent article showed that irisin restores the anticontractile 
function of mouse PVAT in a model of obesity induced by a 
HFD by increasing its expression of heme oxygenase and adi-
ponectin while reducing that of superoxide and TNFα (Hou et 
al. 2016). However, human data’s failed to show a substantial im-
pact of training exercise on circulating irisin and SAT browning 
(Norheim et al. 2014). Although the authors did not investigate 
the contribution of epigenetics to the “re-browning” of PVAT 
in their models, studies in humans showed that a 6 months ex-
ercise training was able to change the DNA methylation profile 
of 7663 genes in adipocytes (Ronn et al. 2013). Interestingly, 
one of the genes found to be hyper methylated and therefore 
inhibited in adipocytes after the 6 months exercise training was 
the histone deacetylase 4 (HDAC4). Further investigations us-
ing the pre-adipocyte cell line 3T3-L1 showed that HDAC4 si-
lencing was associated with increase basal and insulin-induced 
lipogenesis (Ronn et al. 2013). Moreover the exercise training 
has been shown to prevent epigenetic repression of PGC-1alpha 
in the skeletal muscle of mice exposed in utero to a HFD (Laker 
et al. 2014). Such an effect in PVAT could explain the beneficial 
effect of exercise training on mouse PVAT dysfunction induced 
by foetal programming.  Further experiments are needed to de-
termine whether the improvement in PVAT function associated 
with exercise training could be due a myokines dependant “re-
browning” induced through epigenetic regulation.
Epigenetic regulation of adiponectin expression and 
effect on cardiometaboilic diseases
Adiponectin is the main adipokine secreted by adipose tissue and 
represent in an average 0.01% of plasma protein. Adiponectin 
play important metabolic functions by promoting fatty acid 
oxidation, glucose uptake and preventing glucose induced ROS 
synthesis (Shimomura et al. 2006; Van de Voorde et al. 2013). 
Animal studies in models of CMD showed that adiponectin has 
cardioprotecive, anti-inflammatory, -oxidant, -atherogenic, and 
-apoptotic properties (Chow et al. 2007, Goncalves et al. 2015). 
Moreover down regulation of its receptor in obese patients is 
related to insulin resistance and the intramuscular deposition of 
lipids (Yamauchi et al. 2001). The protective role of adiponectin 
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in CMD is further supported by the inverse correlation existing 
between its plasma concentration, BMI and the risk of hyper-
tension (Cnop et al. 2003). Consistently, adiponectin has been 
shown to contribute to mouse PVAT anticontractile function 
(Lynch et al. 2013). Therefore the downregulation of adiponectin 
is a hallmark of adipose tissue dysfunction associated with the 
metabolic syndrome and thereby has been studied intensively. A 
recent study of adiponectin gene methylation statue in adipose 
tissue of obese patients showed a positive correlation with BMI 
suggesting that the downregulation of adiponectin expression 
associated with adipose tissue dysfunction is due to epigenetic 
repression (Houde et al. 2015). In a model of in utero exposure 
to a HFD researchers confirmed the role of adiponectin pro-
moter methylation as the probable cause of decrease circulating 
adiponectin associated with the metabolic syndrome. In another 
research article using the same model, it has been shown that 
epigenetic regulation of adiponectin also involves histone modi-
fications. In this study adiponectin promoter repression in WAT 
was associated to a decreased acetylation and an increase meth-
ylation of histone H3 at lysine 9 (Masuyama et al. 2012). The 
decrease in histone H3 acetylation could be due to the action 
of the Histone Deacetylase 9 (HDAC9), since its inhibition in a 
model of chronic consumption of a HFD in mice was associated 
with an increase adiponectin expression and enhanced energy 
expenditure by promoting Beige adipogenesis (Chatterjee et al. 
2014). Further studies showed that the epigenetic changes in-
duced by in utero exposure to a HFD in the adiponectin promot-
er are transmitted up to 3 generations (Masuyama et al. 2015). 
Although such epigenetic modifications in adiponectin gene has 
not been directly studied in PVAT several studies have shown 
decreases in adiponectin expression at the mRNA and protein 
level in the PVAT of human diseased vessels (Ozen et al. 2015). 
Moreover the detrimental effect of adiponectin repression in 
PVAT on atherosclerosis development has recently been shown. 
Indeed engraftment of PVAT from adiponectin deficient mice 
in a model of collar induced carotid atherosclerosis resulted in 
the accelerated atherosclerotic plaque formation (Li et al. 2015). 
The protective effect of adiponectin in this model was due to 
its ability to promote macrophages autophagy (Li et al. 2015). 
Antonopoulos et al also recently highlighted the role of PVAT 
derived adiponectin as an important anti-oxidant mediator in 
the internal mammary artery of patients suffering with type II 
diabetes (Antonopoulos et al. 2015). However a recent analysis 
of adiponectin expression in the PVAT of patients undergoing 
carotid endarterectomy showed a 2 fold increase of its expres-
sion in symptomatic plaques, suggesting a detrimental role of 
adiponectin in the stability of atherosclerotic plaques (Sharma et 
al. 2015). In conclusion adiponectin expression in PVAT strong-
ly influence vascular biology and is regulated in adipocytes 
partly through epigenetic mechanisms. Further experiments are 
required to fully understand the mechanisms involved in PVAT 
adiponectin repression.
Epigenetic regulation of leptin expression and effects on 
cardiometabolic diseases
Unlike adiponectin, the plasma concentration of leptin, another 
important adipokine mainly secreted by adipocytes, is positively 
correlated to obesity (31.3±24.1 ng/ml vs 7.5±9.3 ng/ml in non-
obese subjects) (Considine et al. 1996). However, these patients 
also present leptin resistance due to decreased expression of the 
leptin receptor. Leptin at first has been involved in energy me-
tabolism and appetite regulation and was perceived has a protec-
tive adipokine with anti-obesogenic and anti-diabetic properties 
(Oral et al. 2002). However, from a cardiovascular perspective, 
leptin has been shown to promote several processes involved 
in CMD such as platelet aggregation, oxidative stress, vascular 
smooth muscle cell proliferation, and inflammation (Beltowski 
2006). The role of epigenetics and particularly DNA methylation 
in leptin expression associated with obesity has recently been 
studied in SAT, VAT and blood cells of severely obese patients. 
The data showed an inverse correlation between leptin promoter 
methylation in blood cells and BMI, suggesting a role for leptin 
promoter demethylation in the hyperleptinemia associated with 
obesity (Houde et al. 2015). The contribution of epigenetics to 
the dysfunctional leptin system associated with the metabolic 
syndrome has also been studied using offspring of mice fed with 
a HFD during pregnancy.  In addition, to increase in body mass, 
dyslipidaemia and glucose intolerance the offspring also present 
hyperleptinemia (Khalyfa et al. 2013). The authors showed that 
the hyperleptinemia induced by a HFD was due to the hypo-
methylation of CpG sites in leptin promoter. Conversely the ex-
pression of the leptin receptor in visceral fat was downregulated 
due to hypermethylation of its promoter (Khalyfa et al. 2013). 
In another study using the same model it has been shown that 
a HFD increases leptin expression in adipocytes through hy-
permethylation of the lysine 20 of histone H4 at its promoter 
(Masuyama et al. 2012). Similar to the modifications in adi-
ponectin promoter the complete loss of the epigenetic marks in-
duced by in utero exposure to a HFD in leptin promoter occurs 
after 3 generations of return to a normal diet (Masuyama et al. 
2015). The increases expression of leptin in PVAT of patients 
with CMD has been observed at the mRNA and protein level 
(Ozen et al. 2015), however the role of epigenetics in this in-
crease remains to be established. Further studies on the epige-
netic regulation of leptin and adiponectin expression in PVAT 
could lead in the future to the identification of targets, allowing 
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the improvement of PVAT function in individuals affected by 
the metabolic syndrome. 
Nerve growth factor a potential marker of adipose 
tissue inflammation in cardiometaboilic diseases
Nerve growth factor (NGF) is a prototype member of the pro-
tein family of neurotrophins (that induce the survival and de-
velopment of neurons) discovered by Rita Levi-Montalcini in 
the early 1950’s. Since then NGF has been involved in a wide 
range of human diseases, including, neurodegenerative and 
psychiatric disorders and CMD (Aloe et al. 2013; Yanev et al. 
2013). Nerve growth factor exerts its biological effects on cells 
by binding to a high affinity receptor called tropomyosin-related 
kinase re ceptor A (TrkA) and a low affinity receptor named p75 
(pan) neurotrophin receptor (p75NTR). Whereas TrkA activation 
mediates protective functions, especially in neurodegenerative 
disorders, p75NTR on the other hand, has been shown to medi-
ate proNGF-induced apoptosis (Aloe et al. 2013). Therefore the 
relative expression of both receptors deeply influences NGF 
pathophysiology. 
From a physiological perspective NGF expression in PVAT 
and other adipose depots may be related to the recruitment 
and maintenance of innervation as recently demonstrated for 
the perivascular innervation of mouse neovessels (Goda et al. 
2016). In a recent review Ayala-Lopez and Watt (2016) high-
lighted the potential role of the sympathetic innervation and 
the adrenergic system of PVAT in obesity-associated hyperten-
sion. In addition to hypertension, altered interactions between 
nerves and adipocytes in PVAT may contribute to atheroscle-
rosis development. Indeed, advanced coronary atherosclerosis 
in human is associated with a reduced amount of NGF and an 
increase in mast cells and vasa vasorum number and p75NTR ex-
pression in the subepicardial adipose tissue (Chaldakov et al. 
2004). Both WAT and BAT has been shown to express NGF and 
brain-derived neurotrophic factor (BDNF) in mouse (Sornelli et 
al. 2009) and in human (Nisoli et al. 1996, Peeraully et al. 2004). 
And obesity was associated with an increase of NGF circulat-
ing level in women (Bullo et al. 2007) and its expression in SAT 
(Atanassova et al. 2014). Moreover, in a model of type 1 diabetes 
induced by streptozotocin injection in rat, NGF expression has 
been shown to increase in both WAT and BAT (Sornelli et al. 
2009). Nevertheless, several studies showed that NGF expres-
sion in fat depots of obese patients was primarily due to non-
adipocyte cells, including stromal vascular cells (Fain 2010). In 
fact, analysis of NGF expression during human adipogenesis 
in vitro revealed a downregulation in differentiated adipocytes 
(Wang et al. 2005). Consistent with this result treatment of 
adipocytes with the PPARγ agonists, rosiglitazone (Ryan et al. 
2008) and 15-deoxy-Δ12,14-PGJ2 (Bullo et al. 2005) results in 
reduced NGF secretion. On the other hand, NGF expression in 
vitro is consistently increase in adipocytes by several atheroscle-
rosis related mediators such as TNFα (Peeraully et al. 2004, Ryan 
et al. 2008), LPS (Ryan et al. 2008) and prostaglandins (Bullo 
et al. 2005). This suggests that the increase expression of NGF 
in PVAT could be due to the recruitment of NGF expressing 
immune cells and a “PVAT whitening” induced by inflamma-
tory mediators. This hypothesis is supported by results show-
ing that stimuli promoting brown adipogenesis such as cold and 
norepinephrine were able to decrease the NGF expression in 
BAT (Nisoli et al. 1996). In contrast with these results other has 
shown increased expression of NGF in BAT of rats and hamsters 
exposed to cold (Nechad et al. 1994). 
Whereas the role of epigenetics in NGF expression by adi-
pocytes has not been studied yet, results obtained in other cell 
types support this possibility. Thus, in a model of chronic neu-
ropathic pain induced by chronic constriction injury of the rat 
sciatic nerve, Tao et al showed that infusion of the brainstem 
nucleus raphe magnus with an HDAC inhibitor was associated 
with an increase in histone H4 acetylation at the NGF promoter 
resulting in increased NGF expression (Tao et al. 2016). Such an 
association between histone H4 acetylation and NGF expression 
has also been observed in the central amygdala in a model of ad-
diction induced by morphine stimulation in rat (Bie et al. 2012). 
In addition to histones acetylation, epigenetic regulation of NGF 
also involves methylation of its promoter. Indeed, during alco-
hol withdrawal in human the decrease in circulating NGF corre-
lates with the increased methylation of CpG islands in the NGF 
promoter of blood cells (Heberlein et al. 2013). Finally, it has 
been shown in human colorectal cancer cells that the expres-
sion of the NGF receptor p75NTR was also frequently repressed by 
methylation of its promoter (Yang et al. 2015).  
In conclusion NGF is consistently induced in adipocytes in 
vitro by inflammatory mediators and in vivo by CMD with an 
important inflammatory component. Further studies are re-
quired to define the sources, modalities of regulation and the 
outcomes of NGF increases in healthy and dysfunctional PVAT 
associated with CMD with particular emphasize on inflamma-
tion and epigenetics.
Role of inflammation in the epigenetic regulation of 
PVAT dysfunction
Inflammation is an important player of the metabolic syndrome 
linking obesity to insulin resistance and has been involved in 
the initiation as well as the rupture of atherosclerotic plaques 
(Bentzon et al. 2014). Therefore PVAT in patients affected by 
the metabolic syndrome is exposed to the influence of systemic 
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and local inflammatory mediators secreted respectively by dys-
functional SAT/VAT and damaged vascular cells and inflamma-
tory cells (e.g. Macrophages) (Verhagen et al. 2011, Fernandez-
Alfonso et al. 2013, Castellon et al. 2016). In a recent article Kim 
Ay et al (2015) investigated the regulation of adiponectin expres-
sion in adipose tissue of obese patients and identified the DNA 
methyl transferase 1 (DNMT1) as the responsible for the epige-
netic silencing of adiponectin in these cells. Whereas adiponec-
tin repression, has been reported in response to endoplasmic 
reticulum stress, mitochondrial dysfunction, hypoxia or inflam-
mation, they found that only proinflammatory cytokines such 
as IL-1β and TNFα was able to induce DNMT1 expression in 
adipocytes (Kim et al. 2015). Interestingly, in a mouse model of 
PVAT inflammation induced by endovascular injury the associ-
ated inhibition of adiponectin expression in PVAT was absent in 
TNFα deficient mice and rescued by adjunction of TNFα to the 
perivascular area of the vessel (Takaoka et al. 2010). Moreover, 
in a mouse model of type 1 diabetes associated with repression 
of adiponectin expression in PVAT, Infliximab (TNFα blocking 
antibody) therapy restored adiponectin expression in mouse 
PVAT and improves endothelial nitric oxide-mediated vasodi-
lation (Nacci et al. 2016). Both results strongly support a role 
for TNFα/DNMT1 in the epigenetic repression of adiponectin 
observed in dysfunctional PVAT. Since IL-1β is also an inducer 
of DNMT1 it could be involved in the repression of adiponec-
tin expression and PVAT thermogenic program. Indeed IL-1β 
stimulation has been shown to inhibit the expression of UCP-1 
induced by cold in vivo and β-adrenergic stimulation of adipo-
cytes in vitro (Goto et al. 2016).
The role of inflammation in the demethylation of the leptin 
gene promoter on the other hand has not been reported yet. 
Active demethylation can be achieved by the action of the ten-
eleven translocation (TET) and the thymine DNA Glycosylase 
(TDG) family enzymes (Kohli et al. 2013). To date, no report 
showed a positive regulation of these enzymes by inflammatory 
mediators in adipocytes. However a recent work aimed at inves-
tigating the role of epicardial fat in a rabbit model of coronary 
atherosclerosis showed that IL-6 stimulation of peri-coronary fat 
was able to increase leptin expression through activation of the 
JAK-STAT3 pathway (Wang et al. 2015). Interestingly, LIF, a cy-
tokine belonging to the IL-6 family of cytokine, has been shown 
to maintain embryonic stem cell pluripotency through the regu-
lation of several DNA demethylases (e.g. DNMT1, 3a/b and 3I) 
and histones deacetylases (HDACs) in a JAK-STAT3 pathway 
dependant fashion (Tang et al. 2013). These results suggest that 
Il-6 could upregulate leptin expression in PVAT by decreasing 
the methylation of its promoter and thereby aggravate athero-
sclerosis development. The promotion of PVAT dysfunction is 
not restricted to IL-6 and TNFα, since in a model of inflam-
mation induced by a HFD it has been shown that Oncostatin 
M expression was increased and responsible for the reduced 
BAT development and SAT browning observed in this model 
(Sanchez-Infantes et al. 2016).  Further studies are required to 
better understand the contribution of epigenetics to the PVAT 
dysfunction induced by inflammatory mediators. 
Role of the AMP-activated protein kinase in the 
epigenetic regulation of PVAT phenotype
AMP-activated protein kinase (AMPK) is a serine/threonine 
protein kinase playing a central role in intracellular energy 
sensing and whole body metabolism (Almabrouk et al. 2014). 
Therefore AMPK has been shown to play important role in the 
regulation of adipocytes metabolism as well as in endothelial and 
vascular smooth muscle cell function (Almabrouk et al. 2014). 
Inhibition of AMPK in response to a HFD has been reported 
in many rat tissues as an early event preceding hyperglycaemia 
or systemic inflammation (Lindholm et al. 2013). Similar to 
what observed in  the offspring of mice fed a HFD, AMPK-1 
deficient mice also present a loss of the anti-contractile poten-
tial of their PVAT (Almabrouk et al. 2016). The authors further 
showed that this loss of anti-contractile function was due to im-
paired adiponectin secretion (Almabrouk et al. 2016). Knowing 
the role of epigenetics in PVAT adiponectin repression induced 
by a HFD, one may think that AMPK-1 could be involved in 
the epigenetic regulation of BAT and PVAT. Indeed, it has been 
shown that an AMPK-1 deficiency in mouse is associated with 
impaired BAT development due to an epigenetic repression 
of PRDM16 expression (Yang et al. 2016). In fact the authors 
showed that AMPK-1 regulates the isocitrate dehydrogenase 2, 
an enzyme involved in the production of α-ketoglutarate a me-
tabolite require for TET mediated DNA demethylation. Thereby 
in AMPK-1 deficient mice the lack of α-ketoglutarate prevent 
PRDM16 promoter demethylation and mRNA expression lead-
ing to the inhibition of the development of their thermogenic fat 
(Yang et al. 2016). 
The involvement of AMPK in epigenetic regulation of ther-
mogenic adipogenesis may also explain the resistance of PVAT 
and BAT to the inflammation induced by a HFD. Indeed a re-
cent report showed that the protective cardiovascular effects, of 
a plant derived steroid sapogenin named diogenin was mediated 
through AMPK activation (Chen et al. 2016). In a rat model of 
PVAT inflammation and endothelial dysfunction induced by a 
HFD the authors showed that diogenin treatment increases the 
basal AMPK expression and prevent the decrease induced by a 
HFD. The increase AMPK activity, then inhibits the PVAT ex-
pression of TNFα, IL-6, MCP-1 and iNOS induced by a HFD 
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while promoting adiponectin, PPARγ and arginase-1 expression 
(Chen et al. 2016). Moreover, using an in vitro model of PVAT/
endothelium interaction induced by exposure of PVAT to fatty 
acids (i.e. palmitic acid) it has been shown that, activation of 
AMPK in PVAT was able to prevent its release of inflammatory 
mediators and thereby its inhibition of the endothelial depend-
ant vasodilatation (Sun et al. 2014). These latter authors found 
that the beneficial effects of AMPK activation was lost in the 
presence of nicotinamide, an inhibitor of the deacetylase and the 
key epigenetic regulator sirtuin 1 (SIRT1). However the exact 
interaction linking AMPK and SIRT1 in PVAT resistance to a 
HFD remains to be fully elucidated. In addition to its potential 
epigenetic regulation of inflammatory genes SIRT1 could also 
improve PVAT function by inducing mitochondrial biogenesis. 
Indeed Mice overexpressing SIRT1 under the control of its own 
promoter, has been shown to be resistant to the metabolic dam-
ages (i.e. adipose mass gain, glucose intolerance, hepatic steato-
sis, inflammation) induced by a HFD in particular by activating 
the PGC-1α leading to increased mitochondrial biogenesis and 
higher energy expenditure (Pfluger et al. 2008). AMPK has been 
involved in endothelial, vascular smooth muscle cells and adi-
pose tissue dysfunction associated with the metabolic syndrome 
(Almabrouk et al. 2014). A better understanding of its beneficial 
effect on PVAT function through epigenetic regulation of key 
adipokines such as leptin and adiponectin could help find new 
targets for managing cardiovascular diseases. 
Coda
There is growing evidence that PVAT dysfunction is a key aspect 
in the pathogenesis of CMD induced by the metabolic syndrome. 
However PVAT research still represents a small percentage of re-
search effort in adipobiology. Although PVAT resembles brown/
beige adipocytes, it arises from a distinct vascular smooth mus-
cle progenitor (a cell lineage yet to be confirmed independently 
by other investigators) showing its singularity among adipocytes 
and its definitive belonging to the vascular structure. Therefore, 
it is difficult to determine to what extent findings in brown and 
beige adipocytes can be applied to PVAT. The data presented in 
this review suggest that epigenetics may play a central role in ad-
ipogenesis, the maintenance of adipocytes phenotype in adult-
hood (Fig. 1) and their dysfunction during metabolic syndrome 
(Fig. 2). The improvements in PVAT dysfunction induced by 
exercise training potentially through epigenetic regulation sup-
port the promises of targeting PVAT epigenetic program in 
preventing and managing CMD associated with the metabolic 
syndrome.
Figure 2. Hypothetical model of perivascular adipose tissue (PVAT) phenotype regulation in health and during the metabolic 
syndrome. In this model hyperglycaemia, dyslipidaemia and inflammation induce a “whitening” of the PVAT by epigenetic re-
pression of their thermogenic programme. The resulting dysfunctional PVAT then favour vascular hypertension, inflammation 
and remodelling through the release of adipose-derived constricting factor (ADCF), nerve growth factor (NGF), cytokines and 
other growth factors. However the beneficial effect of physical activity (exercise training) on PVAT dysfunction suggest that 
other known inducers of BAT such as cold and β-adrenergic stimulation may also induce a PVAT “re-browning” and the restora-
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